1. Bernard Chevalier

    0 Comments Leave a Comment

    1-13 of 13

    1. Mentioned In 13 Articles

    2. Intravascular Healing Is Not Affected by Approaches in Contemporary CTO PCI: The CONSISTENT CTO Study

      Explore ScienceDirect Cardiology
      Intravascular Healing Is Not Affected by Approaches in Contemporary CTO PCI: The CONSISTENT CTO Study
      Objectives The aim of this study was to assess angiographic, imaging, and clinical outcomes following chronic total occlusion (CTO) percutaneous coronary intervention (PCI) with dissection and re-entry techniques (DART) and subintimal (SI) stenting compared with intimal techniques. Background Reliable procedural success and safety in CTO PCI require the use of DART to treat the most complex patients. Potential concerns regarding the durability of DART with SI stenting still need to ...
      Read Full Article
      Mentions: Bernard Chevalier Kings College London

    3. Mechanical performance and healing patterns of the novel sirolimus-eluting bioresorbable Fantom scaffold: 6-month and 9-month follow-up by optical coherence tomography in the FANTOM II study

      Explore Open Heart Cardiology
      Mechanical performance and healing patterns of the novel sirolimus-eluting bioresorbable Fantom scaffold: 6-month and 9-month follow-up by optical coherence tomography in the FANTOM II study
      Objectives We aimed to evaluate the mechanical properties and healing patterns 6 and 9 months after implantation of the sirolimus-eluting Fantom bioresorbable scaffold (BRS). Background The Fantom BRS (Reva Medical, San Diego, USA) has differentiating properties including radiopacity, strut thickness of 125 m, high expansion capacity and has demonstrated favourable mid-term clinical and angiographic outcomes. Methods and results FANTOM II was a prospective, single arm study with implantation of the ...
      Read Full Article
      Mentions: Leiden University Dariusz Dudek Bernard Chevalier

    4. Serial Assessment of Strut Coverage of Biodegradable Polymer Drug-Eluting Stent at 1, 2, and 3 Months After Stent Implantation by Optical Frequency Domain Imaging

      Explore Circulation Cardiology
      Serial Assessment of Strut Coverage of Biodegradable Polymer Drug-Eluting Stent at 1, 2, and 3 Months After Stent Implantation by Optical Frequency Domain Imaging
      Background To assess the vessel-healing pattern of Ultimaster drug-eluting stent using optical frequency domain imaging. Our hypothesis is that biodegradable polymer-based drug-eluting technology allows complete very early strut coverage. Methods and Results The DISCOVERY 1TO3 study (Evaluation With OFDI of Strut Coverage of Terumo New Drug Eluting Stent With Biodegradable Polymer at 1, 2, and 3 Months) is a prospective, single-arm, multicenter study. A total of 60 patients with multivessel ...
      Read Full Article
      Mentions: Terumo Corporation Evelyn Regar Bernard Chevalier

    5. Bioresorbable vascular scaffold treatment induces the formation of neointimal cap that seals the underlying plaque without compromising the luminal dimensions: a concept based on serial optical coherence tomography data

      Explore eurointervention.org Cardiology
      Bioresorbable vascular scaffold treatment induces the formation of neointimal cap that seals the underlying plaque without compromising the luminal dimensions: a concept based on serial optical coherence tomography data
      Aims: To evaluate the implications of an Absorb bioresorbable vascular scaffold (Absorb BVS) on the morphology of the superficial plaques. Methods and results: Forty-six patients who underwent Absorb BVS implantation and 20 patients implanted with bare metal stents (BMS) who had serial optical coherence tomographic examination at baseline and follow-up were included in this analysis. The thin-capped fibroatheromas (TCFA) were identified in the device implantation regions and in the adjacent ...
      Read Full Article
      Mentions: Patrick W. Serruys Hector M. Garcia-Garcia Stephan Windecker

    6. Incidence and Imaging Outcomes of Acute Scaffold Disruption and Late Structural Discontinuity After Implantation of the Absorb Everolimus-Eluting Fully Bioresorbable Vascular Scaffold: OCT Assessment in the ABSORB Cohort B Trial (A Clinical Evaluation of

      Explore ScienceDirect Cardiology
      Incidence and Imaging Outcomes of Acute Scaffold Disruption and Late Structural Discontinuity After Implantation of the Absorb Everolimus-Eluting Fully Bioresorbable Vascular Scaffold: OCT Assessment in the ABSORB Cohort B Trial (A Clinical Evaluation of
      Objectives This study sought to describe the frequency and clinical impact of acute scaffold disruption and late strut discontinuity of the second-generation Absorb bioresorbable polymeric vascular scaffolds (Absorb BVS, Abbott Vascular, Santa Clara, California) in the ABSORB (A Clinical Evaluation of the Bioabsorbable Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions) cohort B study by optical coherence tomography (OCT) post-procedure and ...
      Read Full Article
      Mentions: Patrick W. Serruys Hector M. Garcia-Garcia Stephan Windecker

    7. Bioresorbable vascular scaffold treatment induces the formation of neointimal cap that seals the underlying plaque without compromising the luminal dimensions: a concept based on serial optical coherence tomography data

      Explore eurointervention.org Cardiology
      Bioresorbable vascular scaffold treatment induces the formation of neointimal cap that seals the underlying plaque without compromising the luminal dimensions: a concept based on serial optical coherence tomography data
      Aims: To evaluate the implications of an Absorb bioresorbable vascular scaffold (Absorb BVS) on the morphology of the superficial plaques. Methods and results: Forty-six patients who underwent Absorb BVS implantation and 20 patients implanted with bare metal stents (BMS) who had serial optical coherence tomographic examination at baseline and follow-up were included in this analysis. The thin-capped fibroatheromas (TCFA) were identified in the device implantation regions and in the adjacent ...
      Read Full Article
      Mentions: Patrick W. Serruys Hector M. Garcia-Garcia Stephan Windecker

    8. First Serial Assessment at 6 Months and 2 Years of the Second Generation of Absorb Everolimus-Eluting Bioresorbable Vascular Scaffold: A Multi-Imaging Modality Study

      Explore Circulation Cardiology
      First Serial Assessment at 6 Months and 2 Years of the Second Generation of Absorb Everolimus-Eluting Bioresorbable Vascular Scaffold: A Multi-Imaging Modality Study
      ...hD, 5. Bernard de Bruyne, MD, PhD, 6. Dariusz Dudek, MD, 7. Leif Thuesen, MD, 8. Pieter C. Smits, MD, PhD, 9. Bernard Chevalier, MD, 10. Dougal McClean, MBChB, 11. Jacques Koolen, MD, PhD, 12. Stephan Windecker, MD, 13. ...
      Read Full Article
      Mentions: Patrick W. Serruys Hector M. Garcia-Garcia Stephan Windecker

    10. Differences in Neointimal Thickness Between the Adluminal and the Abluminal Sides of Malapposed and Side-Branch Struts in a Polylactide Bioresorbable Scaffold: Evidence In Vivo About the Abluminal Healing Process

      Explore interventions.onlinejacc.org Cardiology
      Differences in Neointimal Thickness Between the Adluminal and the Abluminal Sides of Malapposed and Side-Branch Struts in a Polylactide Bioresorbable Scaffold: Evidence In Vivo About the Abluminal Healing Process
      ...rd de Bruyne, MD, PhD, Leif Thuesen, MD, John Ormiston, MD||, Dougal R. McClean, MD¶, Stephan Windecker, MD#, Bernard Chevalier, MD**, Dariusz Dudek, MD, PhD, Robert Whitbourn, MD, Salvatore Brugaletta, MD*, Yoshinobu On...
      Read Full Article
      Mentions: Patrick W. Serruys Evelyn Regar Stephan Windecker

    11. Circumferential evaluation of the neointima by optical coherence tomography after ABSORB bioresorbable vascular scaffold implantation: Can the scaffold cap the plaque?

      Explore ScienceDirect Cardiology
      Circumferential evaluation of the neointima by optical coherence tomography after ABSORB bioresorbable vascular scaffold implantation: Can the scaffold cap the plaque?
      ...Ho Heo^a, Vasim Farooq^a, Chrysafios Girasis^a, Robert-Jan van Geuns^a, Leif Thuesen^d, Dougal McClean^e, Bernard Chevalier^f, Stephan Windecker^g, Jacques Koolen^h, Richard Rapoza^i, Karine Miquel-Hebert^j, ...
      Read Full Article
      Mentions: Patrick W. Serruys Hector M. Garcia-Garcia University of Bern

    12. Head-to-Head Comparison of the Neointimal Response Between Metallic and Bioresorbable Everolimus-Eluting Scaffolds Using Optical Coherence Tomography

      Explore interventions.onlinejacc.org Cardiology
      Head-to-Head Comparison of the Neointimal Response Between Metallic and Bioresorbable Everolimus-Eluting Scaffolds Using Optical Coherence Tomography
      ...gal McClean, MD#, Jacques Koolen, MD, PhD, Robert Whitbourn, MD, Dariusz Dudek, MD, Pieter C. Smits, MD, PhD, Bernard Chevalier, MD, Evelyn Regar, MD, PhD*, Susan Veldhof, RN||||, Richard Rapoza, PhD¶¶, John A. Ormiston,...
      Read Full Article
      Mentions: Abbot Patrick W. Serruys Evelyn Regar

    13. Evaluation of the Second Generation of a Bioresorbable Everolimus-Eluting Vascular Scaffold for the Treatment of De Novo Coronary Artery Stenosis: 12-Month Clinical and Imaging Outcomes

      Explore JACC Cardiology
      Evaluation of the Second Generation of a Bioresorbable Everolimus-Eluting Vascular Scaffold for the Treatment of De Novo Coronary Artery Stenosis: 12-Month Clinical and Imaging Outcomes
      Objectives The aim of this study was to demonstrate that the prevention of early scaffold area shrinkage of the ABSORB BVS (Rev.1.1, Abbott Vascular, Santa Clara, California) was sustained and not simply delayed by a few months. Background With improved scaffold design and modified manufacturing process of its polymer, the second iteration of ABSORB (BVS 1.1) has improved performance to prevent a scaffold area reduction at 6 ...
      Read Full Article
      Mentions: Patrick W. Serruys Hector M. Garcia-Garcia Stephan Windecker

    14. Evaluation of the Second Generation of a Bioresorbable Everolimus Drug-Eluting Vascular Scaffold for Treatment of De Novo Coronary Artery Stenosis: Six-Month Clinical and Imaging Outcomes

      Explore Circulation Cardiology
      Evaluation of the Second Generation of a Bioresorbable Everolimus Drug-Eluting Vascular Scaffold for Treatment of De Novo Coronary Artery Stenosis: Six-Month Clinical and Imaging Outcomes
      ...ard de Bruyne, MD, PhD; Evelyn Regar, MD, PhD; Dariusz Dudek, MD; Leif Thuesen, MD; Pieter C. Smits, MD, PhD; Bernard Chevalier, MD; Dougal McClean, MD; Jacques Koolen, MD, PhD; Stephan Windecker, MD; Robert Whitbourn, M...
      Read Full Article
      Mentions: Patrick W. Serruys Evelyn Regar Hector M. Garcia-Garcia
    15. 1-13 of 13
  1. Search:

  2. Categories

    1. Applications:

      Art, Cardiology, Dentistry, Dermatology, Developmental Biology, Gastroenterology, Gynecology, Microscopy, NDE/NDT, Neurology, Oncology, Ophthalmology, Other Non-Medical, Otolaryngology, Pulmonology, Urology

    2. Business News:

      Acquisition, Clinical Trials, Funding, Other Business News, Partnership, Patents

    3. Technology:

      Broadband Sources, Probes, Tunable Sources

    4. Miscellaneous:

      Jobs & Studentships, Student Theses, Textbooks

  4. About Bernard Chevalier

    Bernard Chevalier

    Bernard Chevalier is in the Interventional Cardiology Department at Institute Hospitalier Jacques Cartier in France.

  5. Related Topics

    1. Evaluation of the Second Generation of a Bioresorbable Everolimus Drug-Eluting Vascular Scaffold for Treatment of De Novo Coronary Artery Stenosis: Six-Month Clinical and Imaging Outcomes
      11 articles also mentioned Erasmus University

  6. Quotes

    1. The quality of OFDI imaging system was amazing, and it was surpassed conventional diagnostic imaging technologies. I highly expect the system to contribute to providing even safer and more effective coronary interventions
      In Terumo to Commence Sales of Swept Source OCT Intravascular Imaging System in Europe from July